Literature DB >> 7017019

Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria.

H F Guiot, J W van der Meer, R van Furth.   

Abstract

To reduce the frequency and severity of bacterial infection, selective antimicrobial modulation (SAM) was applied in 39 patients with severely decreased host defense mechanisms. The objective was to eliminate potentially pathogenic aerobic microorganisms with minimal disturbance of the normal anaerobic bacterial flora. Elimination of potentially pathogenic aerobic microorganisms was easily accomplished in patients not infected at hospitalization. The anaerobic flora seemed to be undisturbed, and selection of or overgrowth with resistant microorganisms did not occur. The microbiologic results of the SAM regimen correlated with the incidence of infection. Only three major infections occurred in 23 patients who were free of potentially pathogenic microorganisms; 10 major infections occurred in 16 patients who were not free of potential pathogens. Seven of these 10 infections were present at hospitalization. The incidence of major infections was 47% in the patients on the SAM regimen and 82% in a group of control patients with a similar risk of infection.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7017019     DOI: 10.1093/infdis/143.5.644

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

Review 1.  Review of available trials of selective decontamination of the digestive tract (SDD).

Authors:  H K van Saene; C P Stoutenbeek; A A Gilbertson
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  Bacterial interference by anaerobic species isolated from human feces.

Authors:  M P Wilhelm; D T Lee; J E Rosenblatt
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

Review 3.  Modulation of the host flora.

Authors:  R van Furth; H F Guiot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-01       Impact factor: 3.267

4.  Influence of antibiotics on intestinal tract survival and translocation of environmental Pseudomonas species.

Authors:  S E George; M J Kohan; D A Whitehouse; J P Creason; L D Claxton
Journal:  Appl Environ Microbiol       Date:  1990-06       Impact factor: 4.792

5.  Binding to and antibacterial effect of aztreonam, temocillin, gentamicin and tobramycin on human faeces.

Authors:  M P Hazenberg; A M Pennock-Schröder; J P van de Merwe
Journal:  J Hyg (Lond)       Date:  1985-10

6.  Binding to and antibacterial effect of ampicillin, neomycin and polymyxin B on human faeces.

Authors:  M P Hazenberg; A M Pennock-Schröder; M Van den Boom; J P Van de Merwe
Journal:  J Hyg (Lond)       Date:  1984-08

7.  Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases.

Authors:  W Kern; E Kurrle; T Schmeiser
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

8.  Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin.

Authors:  H F Guiot; W G Peters; P J van den Broek; J W van der Meer; J A Kramps; R Willemze; R van Furth
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

9.  Selective gut decontamination with nalidixic acid or trimethoprim-sulfamethoxazole for infection prophylaxis in neutropenic cancer patients: relationship of efficacy to antimicrobial spectrum and timing of administration.

Authors:  E J Bow; E Rayner; B A Scott; T J Louie
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

10.  Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Authors:  G H Talbot; P A Cassileth; L Paradiso; R Correa-Coronas; L Bond
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.